Neostigmine is a cholinesterase inhibitor used in the symptomatic treatment of myasthenia gravis by improving muscle tone. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
- Mechanism
- Curator reviewed
Neostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. The drug inhibits acetylcholinesterase which is responsible for the degredation of acetylcholine. So, with acetylcholinesterase inhibited, more acetylcholine is present By interfering with the breakdown of acetylcholine, neostigmine indirectly stimulates both nicotinic and muscarinic receptors which are involved in muscle contraction.. It does not cross the blood-brain barrier.
- Primary indication
- Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.Curator reviewed · 8 structured indications
- Formula / weight
- C12H19N2O2 · 223.2915 g/mol (avg)
- First approval
- Canada, 1999 · United States, 2013
- Also known as
- Eustigmin · Eustigmine
- Brand names
Resolves to
ALWKGYPQUAPLQC-UHFFFAOYSA-NSMILESCN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Neostigmine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account